Pyxis Oncology, Inc. Profile Avatar - Palmy Investing

Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targ…

Biotechnology
US, Cambridge [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of PYXS's Analysis
CIK: 1782223 CUSIP: 747324101 ISIN: US7473241013 LEI: - UEI: -
Secondary Listings
PYXS has no secondary listings inside our databases.